Antibody Conjugates Drug Market Report 2024 (Global Edition)

Global Antibody Conjugates Drug Market Report 2024 Market Size Split by Product (Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, Others), by Disease Type (Breast Cancer, Blood Cancer, Others), b...

Antibody Conjugates Drug Market Report Description

We have various report editions of Antibody Conjugates Drug Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Antibody Conjugates Drug Market Insights Video

Competitive Landscape of the Antibody Conjugates Drug Market

The market for antibody conjugates drugs, or ADCs, is extremely competitive, with Pfizer, AstraZeneca, and Roche at the forefront of the industry. These companies place a high priority on tactical alliances, acquisitions, and significant R&D to strengthen their ADC portfolios. The emergence of new biotech companies in the market is driving innovation. A race to create next-generation ADCs that target a wider spectrum of diseases and have better efficacy and safety is what distinguishes the competitive field.

In July 2023, ImmunoGen, Inc. and ImmunoBiochem entered into a multi-target license and option agreement to yield next-generation antibody-drug conjugates. (Source:https://investor.immunogen.com/news-releases/news-release-details/immunogen-announces-multi-target-license-and-option-agreement) ADC (differentiated antibody-drug conjugate) therapy for solid tumors will be advanced in July 2023 through a collaboration between DualityBio and BeiGene. (Source:https://ir.beigene.com/news/beigene-and-dualitybio-announce-partnership-to-advance-differentiated-antibody-drug-conjugate-adc-therapy-for-solid/8420cc36-bac6-4716-85e6-92db7b665f9b/) In June 2023, Synaffix B.V., a biotechnology business that commercializes clinical-stage technological platforms for the creation of antibody-drug conjugates, was bought by Lonza. (Source: https://www.lonza.com/news/2023-06-01-07-00)

Top Companies Market Share in Antibody Conjugates Drug Industry: (In no particular order of Rank)

• F. Hoffmann-La Roche Ltd (Switzerland)
• Takeda Pharmaceutical Company Limited (Japan)
• Pfizer Inc. (US)
• Limited (Japan)
• Seagen Inc. (US)
• Gilead Sciences
• Inc. (US)
• Astellas Pharma Inc (Japan)
• AstraZeneca (UK)
• Zydus Group (India)
• ADC Therapeutics SA (Switzerland)
• ImmunoGen
• Inc. (US)
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Antibody Conjugates Drug Market

Which Region Dominates the Antibody Conjugates Drug Market in 2024?

According to Cognitive Market Research, North America currently dominates the Antibody Conjugates Drug market, and the region is expected to have significant growth during the projected period. The market for antibody conjugate drugs (ADCs) is anticipated to develop at the highest pace in North America because of the region's substantial R&D investments, strong healthcare system, and concentration of top pharmaceutical businesses. The high rate of cancer in the area is driving up demand for cutting-edge treatments like ADCs. Favorable regulatory frameworks and quicker approval procedures from organizations like the FDA also facilitate market expansion. North America is positioned as a major driver of the growth of the global ADC market due to its emphasis on personalized medicine and abundance of qualified experts, which support the development and implementation of ADCs.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). The Asia Pacific region has the potential to propel substantial growth in the Antibody Conjugates Drug (ADC) Market because of its developing healthcare system, rising cancer incidence, and growing need for cutting-edge treatments. Governments in the area are making significant investments in biotechnology and healthcare, which is encouraging the growth of ADCs. Market acceptance is also being expedited by rising awareness of targeted medicines and rising clinical trial participation. Asia Pacific will play a major role in the future expansion of the global ADC market due to the region's high patient population and expanding access to healthcare services.

The current report Scope analyzes Antibody Conjugates Drug Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Antibody Conjugates Drug Market

According to Cognitive Market Research, the global Antibody Conjugates Drug market size was estimated at USD 9825.2 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 3930.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.7% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Antibody Conjugates Drug market with a market size of USD 3100.83 million in 2024 and is projected to grow at a CAGR of 9.5% during the forecast period. In the US, the market for antibody-drug conjugates is fueled by the rising incidence of cancer and the growing emphasis on precision medicine (ADCs).
• The Canada Antibody Conjugates Drug market had a market share of USD 471.61 million in 2024 and is projected to grow at a CAGR of 10.5% during the forecast period. In Canada, Innovation in the ADC market is driven by a burgeoning biotechnology sector and advantageous policies.
• The Mexico Antibody Conjugates Drug market is projected to witness growth at a CAGR of 10.2% during the forecast period, with a market size of USD 357.64 million in 2024.

Europe Antibody Conjugates Drug Market

According to Cognitive Market Research, the global Antibody Conjugates Drug market size was estimated at USD 9825.2 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 2947.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2024 to 2031.

• The United Kingdom Antibody Conjugates Drug market had a market share of USD 495.19 million in 2024 and is projected to grow at a CAGR of 10.8% during the forecast period. The existing clinical research environment in the United Kingdom facilitates the development and approval of ADCs.
• The France Antibody Conjugates Drug market is projected to witness growth at a CAGR of 9.2% during the forecast period, with a market size of USD 271.18 million in 2024.
• According to Cognitive Market Research, the German Antibody Conjugates Drug market size was valued at USD 583.62 million in 2024 and is projected to grow at a CAGR of 10.2% during the forecast period. The ADC market is driven by Germany's top pharmaceutical industry, which focuses on biotechnology and cancer.
• The Italy Antibody Conjugates Drug market is projected to witness growth at a CAGR of 9.4% during the forecast period, with a market size of USD 253.49 million in 2024.
• The Russia Antibody Conjugates Drug market is projected to witness growth at a CAGR of 9.0% during the forecast period, with a market size of USD 456.87 million in 2024.
• The Spain Antibody Conjugates Drug market is projected to witness growth at a CAGR of 9.1% during the forecast period with a market size of USD 241.70 million in 2024
• The Luxembourg Antibody Conjugates Drug market is projected to witness growth at a CAGR of 10.1% during the forecast period, with a market size of USD 91.37 million in 2024.
• The Portugal Antibody Conjugates Drug market is projected to witness growth at a CAGR of 9.8% during the forecast period, with a market size of USD 61.90 million in 2024.
• The Greece Antibody Conjugates Drug market is projected to witness growth at a CAGR of 10.3% during the forecast period, with a market size of USD 35.37 million in 2024.
• The Rest of Europe's Antibody Conjugates Drug market is projected to witness growth at a CAGR of 8.7% during the forecast period, with a market size of USD 456.87 million in 2024.

Asia Pacific Antibody Conjugates Drug Market

According to Cognitive Market Research, the global Antibody Conjugates Drug market size was estimated at USD 9825.2 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 2259.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.5% from 2024 to 2031.

• According to Cognitive Market Research, the China Antibody Conjugates Drug market size was valued at USD 1016.91 million in 2024 and is projected to grow at a CAGR of 13.0% during the forecast period. Antibody Conjugates Drugs surged in China due to the need for sophisticated cancer treatments, such as ADCs, which are being driven by the rising middle class and increased government spending on healthcare.
• The Japan Antibody Conjugates Drug market is projected to witness growth at a CAGR of 12.0% during the forecast period, with a market size of USD 311.85 million in 2024.
• The India Antibody Conjugates Drug market had a market share of USD 271.18 million in 2024 and is projected to grow at a CAGR of 15.3% during the forecast period. The manufacturing of pharmaceuticals in India is growing, which helps with ADC production and delivery.
• The South Korean Antibody Conjugates Drug market is projected to witness growth at a CAGR of 12.6% during the forecast period, with a market size of USD 225.98 million in 2024.
• The Australian Antibody Conjugates Drug market is projected to witness growth at a CAGR of 13.2% during the forecast period, with a market size of USD 117.51 million in 2024.
• The South East Asia Antibody Conjugates Drug market is projected to witness growth at a CAGR of 14.5% during the forecast period, with a market size of USD 155.93 million in 2024.
• The Rest of Asia Pacific Antibody Conjugates Drug market is projected to witness growth at a CAGR of 13.3% during the forecast period, with a market size of USD 160.45 million in 2024.

South America Antibody Conjugates Drug Market

According to Cognitive Market Research, the global Antibody Conjugates Drug market size was estimated at USD 9825.2 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 491.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.9% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Antibody Conjugates Drug market size was valued at USD 210.26 million in 2024 and is projected to grow at a CAGR of 11.5% during the forecast period. Antibody Conjugates Drugs flourished in Brazil because the market for ADCs in Brazil is driven by government initiatives targeted at expanding access to cancer therapies.
• Argentina's Antibody Conjugates Drug market had a market share of USD 82.53 million in 2024 and is projected to grow at a CAGR of 11.8% during the forecast period. In Argentina, the approval and commercialization of ADCs can be facilitated by a regulatory structure that is favorable.
• Colombia Antibody Conjugates Drug market is projected to witness growth at a CAGR of 10.7% during the forecast period, with a market size of USD 43.72 million in 2024.
• Peru Antibody Conjugates Drug market is projected to witness growth at a CAGR of 11.1% during the forecast period, with a market size of USD 40.28 million in 2024.
• Chile Antibody Conjugates Drug market is projected to witness growth at a CAGR of 11.2% during the forecast period, with a market size of USD 35.37 million in 2024.
• The Rest of Latin America's Antibody Conjugates Drug market is projected to witness growth at a CAGR of 10.0% during the forecast period, with a market size of USD 79.09 million in 2024.

Middle East and Africa Antibody Conjugates Drug Market

According to Cognitive Market Research, the global Antibody Conjugates Drug market size was estimated at USD 9825.2 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 196.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.2% from 2024 to 2031..

• The GCC Countries Antibody Conjugates Drug market is projected to witness growth at a CAGR of 12.0% during the forecast period, with a market size of USD 84.10 million in 2024. Antibody Conjugates Drug sales flourish in GCC countries due to the GCC population's rising disposable wealth, which is fueling demand for cutting-edge medical care, including novel treatments.
• The Egypt Antibody Conjugates Drug market is projected to witness growth at a CAGR of 11.5% during the forecast period, with a market size of USD 20.63 million in 2024.
• The South Africa Antibody Conjugates Drug market is projected to witness growth at a CAGR of 12.2% during the forecast period, with a market size of USD 31.05 million in 2024. Antibody Conjugates Drug sales flourished in South Africa due to the demand being driven by patients and healthcare professionals' growing understanding of the advantages of targeted medicines like ADCs.
• The Turkey Antibody Conjugates Drug market is projected to witness growth at a CAGR of 10.7% during the forecast period, with a market size of USD 16.90 million in 2024.
• The Nigeria Antibody Conjugates Drug market is projected to witness growth at a CAGR of 10.3% during the forecast period, with a market size of USD 20.63 million in 2024.
• The Rest of the MEA Antibody Conjugates Drug market is projected to witness growth at a CAGR of 10.2% during the forecast period, with a market size of USD 23.19 million in 2024.

Antibody Conjugates Drug Market Analysis

How are Segments Performing in the Global Antibody Conjugates Drug Market?

Antibody Conjugates Drug Market Product Segment Analysis

According to Cognitive Market Research, kadcyla is likely to dominate the Antibody Conjugates Drug Market over the forecast period. Because of its effectiveness in treating HER2-positive breast cancer, especially in patients who have not responded to prior treatments, Kadcyla is in high demand in the antibody conjugates drug (ADC) market. As opposed to conventional chemotherapy, Kadcyla's targeted delivery method, which combines trastuzumab with a cytotoxic drug, offers better efficacy and fewer adverse effects. Kadcyla's status as a pivotal oncology treatment is cemented by the growing demand for the drug as HER2-positive breast cancer becomes more common and as medical professionals look for more individualized treatment alternatives.

The enhertu are the fastest-growing segment in the Antibody Conjugates Drug Market. Enhertu's effectiveness in treating HER2-positive breast cancer, particularly in patients who have not responded to earlier treatments, is driving up demand for the drug in the antibody conjugates drug (ADC) market. Its novel approach of combining a strong cytotoxic drug with an antibody that targets HER2 has shown remarkable success, even in situations where HER2 expression is low. It is anticipated that demand for Enhertu will continue its strong rising trend as knowledge of HER2-driven tumors grows and as clinical trials investigating its usage in other cancers are conducted.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Antibody Conjugates Drug Industry. Request a Free Sample PDF!

Antibody Conjugates Drug Market Disease Type Segment Analysis

According to Cognitive Market Research, the category with the highest market share is breast cancer. The growing prevalence of HER2-positive breast cancer, a subtype that greatly benefits from targeted therapy, is driving up demand for antibody conjugate drugs (ADCs) in breast cancer. When compared to traditional chemotherapy, ADCs such as Kadcyla and Enhertu have shown higher performance because they deliver cytotoxic chemicals directly to cancer cells while protecting healthy tissue and minimizing adverse effects. The market is expanding due to the growing need for targeted medicines in the treatment of breast cancer as new ADCs acquire regulatory approval and personalized medicine finds popularity.

In the Antibody Conjugates Drug Market, the blood cancer segment has been expanding at a rapid pace. Because of their tailored therapeutic strategy, antibody conjugate drugs (ADCs) are becoming more and more popular in blood cancer. They are especially useful in treating hematologic malignancies like lymphoma and leukemia. ADCs provide a cutting-edge method of administering chemotherapy straight to cancer cells while limiting harm to healthy cells and lowering side effects. Healthcare professionals are embracing ADCs for blood malignancies more and more as research progresses and more are approved. The market desire for less hazardous and more effective treatment choices is driving this increased adoption.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Antibody Conjugates Drug Linker Type Segment Analysis

Antibody Conjugates Drug Market Linker Type Segment Analysis

According to Cognitive Market Research, the cleavable segment holds the largest market share. Cleavable linkers are the most frequently used technology for an effective outcome of ADCs in cancer treatment. They can release cytotoxins from ADCs and stay stable in the bloodstream for longer. For instance, the NMPA authorized Seagen's & Takeda's Adcetris in May 2020 for the treatment of relapsed systemic anaplastic large cell lymphoma (sALCL) and relapsed Hodgkin's lymphoma in China. It is anticipated that these reasons will propel the growth of the cleavable linker segment.

Non-cleavable is anticipated to be the fastest-growing segment in the Antibody Conjugates Drug market. Non-cleavable linker types are becoming more and more popular in the market for antibody conjugate drugs (ADCs) because of their stability and capacity to transport cytotoxic chemicals directly to target cells. Until the whole complex is taken up by the cytotoxic agent and the cancer cells are discharged, non-cleavable linkers guarantee that the drug stays bound to the antibody. By using this method, off-target effects are decreased, and the therapeutic index of ADCs is raised. The demand for ADCs with non-cleavable linkers is anticipated to increase as more of them show clinical success, propelling growth in this market niche.

• Non-Cleavable
• Cleavable

Antibody Conjugates Drug Target Segment Analysis

Antibody Conjugates Drug Market Target Segment Analysis

According to Cognitive Market Research, HER2 segment dominates the market. Antibody Conjugated Drugs (ADCs) that target HER2 are in great demand because breast cancer is one of the most common malignancies that test positive for HER2. By precisely targeting and delivering cytotoxic drugs to cancer cells that overexpress HER2, HER2-targeted ADCs like Kadcyla and Enhertu offer increased efficacy and minimize adverse effects. HER2-targeted ADCs are an essential part of the therapy toolkit for these aggressive cancer types because of the increased demand brought about by the sustained emphasis on personalized medicine and continuous research into HER2-related tumors.

CD22 is projected to be the fastest-growing segment in the Antibody Conjugates Drug market. The increasing success of antibody-conjugated drugs (ADCs) in treating hematologic malignancies, especially leukemias and B-cell lymphomas, has led to a desire for ADCs that target CD22. ADCs target CD22 because it is a cell surface marker that is frequently overexpressed in these malignancies. Targeting CD22, medications such as Inotuzumab Ozogamicin directly transport cytotoxic chemicals to malignant B-cells, enhancing therapeutic outcomes while limiting harm to healthy tissues. The market is growing as a result of the expanding role that CD22-targeted ADCs play in treating B-cell malignancies and the development of more of these drugs.

• HER2
• CD22
• CD30
• Others

Antibody Conjugates Drug Payload Type Segment Analysis

Antibody Conjugates Drug Market Payload Type Segment Analysis

According to Cognitive Market Research, the MMAE/auristatin segment dominates the market. Due to their strong cytotoxic effects and potential for targeted therapy, antibody conjugate drugs (ADCs) containing MMAE (monomethyl auristatin E) or auristatin payloads are becoming more and more in demand. ADCs employ the potent microtubule-disrupting chemical MMAE to administer chemotherapy directly to cancer cells, therefore increasing therapeutic efficacy and reducing systemic toxicity. Medications that use MMAE, such as Brentuximab Vedotin, have demonstrated promising clinical outcomes when treating hematologic malignancies. The market's need for MMAE-based ADCs is rising as a result of these treatments' effectiveness in identifying and eliminating cancer cells.

Calicheamicin is projected to be the fastest-growing segment in the Antibody Conjugates Drug market. Antibody Conjugated Drugs (ADCs) with calicheamicin payloads are becoming more and more popular because of their strong and extremely focused cytotoxic effects. In order to deliver targeted chemotherapy directly to cancer cells and cause significant tumor cell killing while minimizing damage to healthy tissues, ADCs employ calicheamicin, a potent DNA-damaging chemical. Acute myeloid leukemia (AML) has been successfully treated with medications such as Mylotarg, which uses calicheamicin. The growing acceptance and demand of calicheamicin payloads in the ADC market is a result of their efficacy in identifying and eradicating cancer cells.

• MMAE/auristatin
• Calicheamicin
• Maytansinoids
• Others

Author's Detail

Sneha Mali

Research Analyst at Cognitive Market Research

LinkedIn

Profile

I am a research analyst working in various domains including the Consumer Goods domain, and my primary responsibility is to conduct thorough research on various subjects and provide valuable insights to support client requirements. I have knowledge of research methodologies, and data mining which enables me to analyze large data sets, draw meaningful conclusions, and communicate them effectively. I stay up-to-date with the latest research trends, methodologies, and technologies to ensure that my research is accurate, relevant, and impactful.

Author's Conclusion